In terms of endogenous growth, due to multiple equity changes, Pacific Shuanglin's business development was relatively slow before the 14th Five-Year Plan period. The company achieved rapid growth in business performance in 2019 and 2020 by improving its corporate governance structure, enhancing decision-making and operational efficiency, strengthening refined management, reducing operating costs, addressing legacy issues, establishing long-term incentive mechanisms, and introducing modern management systems.

During the COVID-19 pandemic, the intravenous immunoglobulin (pH4) produced by the company was included in the treatment plan by several medical institutions and included in the list of drugs reserved by China's Ministry of Industry and Information Technology because of its ability to enhance the anti-infection ability of the body and improve immunity. This drew attention from the blood product industry.